- Gastrointestinal stromal tumor
- Sarcoma
- Soft tissue sarcoma
Daniel Lefler, MD
he/him
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
Penn Medicine Provider
About me
- Assistant Program Director, Hematology/Oncology Fellowship
- Associate Clinical Director, Sarcoma Medical Oncology
- Assistant Professor of Clinical Medicine (Hematology-Oncology)
My education and training
- Medical School: Cooper Medical School of Rowan University
- Residency: University of Pennsylvania Health System
- Fellowship: Thomas Jefferson University Hospital
Spoken languages
English
English
Reviews
240 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Pennsylvania Hospital: On the medical staff, but does not have privileges to treat patients in the hospital.
Qualifications and experience
- Hematology, 2023
- Medical Oncology, 2023
- Internal Medicine, 2019
- American Medical Association, National
- American Society of Clinical Oncology, National
- Connective Tissue Oncology Society, National
- ECOG-ACRIN, National
- National Comprehensive Cancer Network, National
- Penn Sarcoma Program
Treatments and conditions
Research
Publications
Baldi GG, Giani C, Ljevar S, Denu RA, Napolitano A, Han I, Brunello A, Bhadri V, Sebio A, Andelkovic V, Campos F, Scanferla R, Abreu MH, Desar IME, Ogura K, Wong DD, Bae S, Bakhshi S, Lefler DS, Marquina G, Mazzocca A, Nakazawa MS, Thway K, Kim HS, Chiusole B, Connolly EA, Terés R, Antonescu C, Bellan E, V M G Bovée J, Davis JL, P Dei Tos A, Di Blasi E, Lazar AJ, Sbaraglia M, Schaefer IM, Taverna S, Gronchi A, Miceli R, Chen TW, Stacchiotti S Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium , Eur J Cancer: 2026
Aleixo G, Hartner L, Diamond M, Wong W, Allen JW, Yi I, Costa P, Lefler DS Liposomal Versus Conventional Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas: Observational Multi-Institutional Cohort of 8.5-Year Experience , JCO Oncol Pract: 2026
Lefler DS, Nassif Haddad EF, Nohria A, Agulnik M, Crane J, Fradley MG Sarcoma: Cardiovascular and Oncologic Considerations: JACC: CardioOncology State-of-the-Art Review , JACC CardioOncol: 2025
Lefler, D.S., Perez, J.E., DeMatteo, R.P. Cancer testis antigens as targets in KIT11-mutated, imatinib-resistant GIST , Connective Tissue Oncology Society Annual Meeeting, Boca Raton, FL: 2025
Daniel S Lefler, Andrew Elliott, Wei Jiang, Ubaldo Martinez-Outschoorn, Jude Al-Sabah, Daniel M Freed, Caitlin M King, Robert G Maki, Richard F Riedel, Jaime F Modiano, Daniel Hübschmann, Hanno Glimm, Stefan Fröhling, Matthew Oberley, Sosipatros A Boikos, Atrayee Basu Mallick Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma , JCO Precis Oncol, 9: 2025,e2500149.
Mohammad S Farooq, Neha Shafique, Gracia M Vargas, Jennifer Guo, John T Miura, Daniel S Lefler, Giorgos C Karakousis Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis , J Surg Oncol, 131(8): 2025,1683-1691.
Lefler, D.S., Maki, R.G., Somaiah, N., …Basu Mallick, A. Characterizing the genomic landscape of perivascular epithelioid cell family of tumors in a real-world patient population using the Foundation Medicine genomic database , Connective Tissue Oncology Society Annual Meeting, San Diego, CA: 2024
Lefler, D.S., Moding, E.J., Basu Mallick, A mTOR activity: a biomarker for chemo- and immunotherapy response and outcomes in sarcomas , Connective Tissue Oncology Society Annual Meeting, San Diego, CA: 2024
Lefler, D.S., Elliott, A., Blomain, E.S., …Basu Mallick, A Characterizing patterns of mTORC1 activation across sarcomas using single-sample gene set enrichment analysis (ssGSEA) and a national biomarker database , American Society of Clinical Oncology Annual Meeting, Chicago,IL: 2024
Jirka GW, Lefler DS, Russo J, Bashir B. Colon adenocarcinoma and Birt-Hogg-Dubé syndrome in a young patient: case report and exploration of pathologic implications , Cancer Biol Ther, 24(1): 2023,2184153